{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alterity Therapeutics Limited"},"Symbol":{"label":"Symbol","value":"ATHE"},"Address":{"label":"Address","value":"460 BOURKE STREET LEVEL 3, MELBOURNE, 3000, Australia"},"Phone":{"label":"Phone","value":"+61 393494906"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders."},"CompanyUrl":{"label":"Company Url","value":"https://www.alteritytherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David A. Stamler","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}